Source:http://linkedlifedata.com/resource/pubmed/id/16025496
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-7-21
|
pubmed:abstractText |
The combination of high aminotransferases (hepatocellular injury) and jaundice has been reported to lead to a mortality rate of 10% to 50% for different drugs, a phenomenon known as "Hy's rule." However, Hy's rule has never been validated, and limited data exist on predictors for outcome in hepatocellular and other forms of drug-induced liver disease. All reports of suspected hepatic adverse drug reactions received by the Swedish Adverse Drug Reactions Advisory Committee (1970-2004) were reviewed. Cases with bilirubin levels 2 or more times the upper limit of normal (ULN) were analyzed. A total of 784 cases were retrieved-409 with hepatocellular injury, 206 with cholestatic injury, and 169 with mixed liver injury. The mortality/transplantation rate was 9.2%, and bilirubin (median 18.7 x ULN [IQR 12.6-25]; range 4.5-42) was higher (P < .0001) in the deceased/transplant recipients compared with the surviving patients (median 5.5 x ULN [IQR 3.3-9.5]; range 2.0-38). A total of 7.8% with cholestatic and 2.4% with a mixed pattern died. The mortality rate in hepatocellular injury for different drugs varied from 40% (6 of 15) for halothane to 0% (0 of 32) for erythromycin, in total 12.7%. Using logistic regression analysis, age, aspartate aminotransferase (AST) and bilirubin were found to independently predict death or liver transplantation in the hepatocellular group, whereas among patients with cholestatic/mixed liver injury, bilirubin was the only independent predictor. In conclusion, hepatocellular jaundice has a high but variable mortality rate, depending on the drug involved. The AST and bilirubin levels are the most important predictors of death or liver transplantation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
481-9
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:16025496-Adult,
pubmed-meshheading:16025496-Aged,
pubmed-meshheading:16025496-Aged, 80 and over,
pubmed-meshheading:16025496-Cholestasis,
pubmed-meshheading:16025496-Drug-Induced Liver Injury,
pubmed-meshheading:16025496-Female,
pubmed-meshheading:16025496-Humans,
pubmed-meshheading:16025496-Jaundice,
pubmed-meshheading:16025496-Liver,
pubmed-meshheading:16025496-Liver Diseases,
pubmed-meshheading:16025496-Liver Failure,
pubmed-meshheading:16025496-Liver Transplantation,
pubmed-meshheading:16025496-Logistic Models,
pubmed-meshheading:16025496-Male,
pubmed-meshheading:16025496-Middle Aged,
pubmed-meshheading:16025496-Prognosis
|
pubmed:year |
2005
|
pubmed:articleTitle |
Outcome and prognostic markers in severe drug-induced liver disease.
|
pubmed:affiliation |
Section of Gastroenterology and Hepatology, Department of Internal Medicine, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden. einar.bjornsson@medic.qu.se
|
pubmed:publicationType |
Journal Article
|